News and Updates

New Publication Alert! Breakthrough T1D spearheaded a paper titled “International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes” that was published in Diabetologia. This is an important step toward integrating general population screening for type 1 diabetes (T1D) into clinical practice globally. Read on to learn more about […]

This article was written by Francine Maloney, MPH (Director, Implementation and Director, U.S. Coalition for Early T1D Action) and Umila Singh, MFA (Design Specialist, Innovation) from Ariadne Labs at Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health. The U.S. Coalition for Early T1D Action has utilized our Participant Advisory Council (PAC) […]

ADA’s 86th Scientific Sessions This event is one of the largest diabetes conferences in the world, bringing together over 11,000 attendees to share and learn about cutting-edge research and advancements toward cures. Each year, Breakthrough T1D-funded researchers highlight their work, demonstrating the progress we’re making toward achieving our mission. Leading experts will present over 100 […]

ADA’s 86th Scientific Sessions This event is one of the largest diabetes conferences in the world, bringing together over 11,000 attendees to share and learn about cutting-edge research and advancements toward cures. Each year, Breakthrough T1D-funded researchers highlight their work, demonstrating the progress we’re making toward achieving our mission. Leading experts will present over 100 […]

Breakthrough T1D is focused on developing drugs, or disease-modifying therapies (DMTs), that change the course of T1D for everyone affected by it—and those yet to be. That means slowing or halting the progression of the disease, preventing it from ever occurring, and reversing it entirely through immune therapies and beta cell therapies.  Note: To enlarge the image below, left click […]

Tzield is the first approved disease-modifying therapy for type 1 diabetes, but Breakthrough T1D will make sure it’s not the last.

Closing the gap between access to and adoption of type 1 diabetes therapies is a mission priority. Chris Dunn represents these efforts in action.

Although its exact causes are unknown, researchers have uncovered type 1 diabetes risk factors that increase a person's likelihood of developing the condition.

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

J.J. Spaun’s diagnosis story highlights the importance of screening and monitoring for type 1 diabetes in people of all ages.